Stock Comparison
LLY vs TERN
Eli Lilly and Co vs Terns Pharmaceuticals Inc
Who's the better investment? Let's break it down.
The Verdict
LLY takes this one.
This one's close — only 0.4 points separating them. LLY wins by a hair, but both deserve a closer look.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
LLY
Metric
TERN
Market Cap
P/E Ratio
Lower may indicate better value
Price/Book
Profitability & Growth
LLY
Metric
TERN
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
LLY
Metric
TERN
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
LLY
TERN
What Could Go Wrong
For former shareholders, the only remaining 'risk' would have been if the Merck acquisition (announced in March 2026) had failed to close by May 5, 2026. However, the deal completed as planned, and Te...
Red Flags
- 🚩Company delisted on May 5, 2026.
- 🚩No longer trades publicly.
- 🚩All shareholder equity converted to cash at $53.00/share.
Competitive Moat
LLY
Rating
🛡️ Wide
Trend
📈 Expanding
TERN
Rating
🛡️ None
Trend
➡️ Not Applicable
Investment Thesis
Eli Lilly is a pharmaceutical leader with a multi-decade growth runway, primarily driven by its innovative GLP-1 franchise (Mounjaro/Zepbound) and a robust pipeline in Alzheimer's and other high-demand therapeutic areas. Its strong R&D, manufacturing scale, and expanding market share position it for sustained, above-average growth within the healthcare sector, making it a core holding for long-ter...
Full LLY AnalysisThe investment thesis for Terns Pharmaceuticals as a high-risk, high-reward 10x growth opportunity is entirely negated. The company was acquired by Merck for $53.00 per share and subsequently delisted on May 5, 2026. All independent growth potential has been capitalized and transferred to Merck. Terns no longer represents a viable investment for public equity investors.
Full TERN AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achieving a 10x return ($10 trillion+) within a 3-5 year timeframe fundamentally unrealistic. The major gr...
Full LLY AnalysisScore Change Explanation: The score has been maintained at an extremely low level (0/100, down from the previous 1/100) to reflect the definitive and irreversible change in Terns Pharmaceuticals' status. On May 5, 2026, Merck completed its acquisition of TERN for $53.00 per share, and the company has since been delisted from Nasdaq. This corporate action entirely eliminates TERN's independent existence as a public company and, consequently, any possibility of it generating 10x growth for public ...
Full TERN AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.